DK2146742T3 - Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder - Google Patents

Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder

Info

Publication number
DK2146742T3
DK2146742T3 DK08737810.5T DK08737810T DK2146742T3 DK 2146742 T3 DK2146742 T3 DK 2146742T3 DK 08737810 T DK08737810 T DK 08737810T DK 2146742 T3 DK2146742 T3 DK 2146742T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
methods
melanomas
preparing
Prior art date
Application number
DK08737810.5T
Other languages
English (en)
Inventor
Jose Mordoh
Maria Marcela Barrio
Euw Erika Maria Von
Original Assignee
Consejo Nac Invest Cient Tec
Fundacion Sales
Inisbiotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec, Fundacion Sales, Inisbiotech Llc filed Critical Consejo Nac Invest Cient Tec
Application granted granted Critical
Publication of DK2146742T3 publication Critical patent/DK2146742T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08737810.5T 2007-04-11 2008-04-11 Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder DK2146742T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
PCT/IB2008/051385 WO2008126039A2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods

Publications (1)

Publication Number Publication Date
DK2146742T3 true DK2146742T3 (da) 2012-10-22

Family

ID=39590605

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08737810.5T DK2146742T3 (da) 2007-04-11 2008-04-11 Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder

Country Status (17)

Country Link
US (1) US8501168B2 (da)
EP (1) EP2146742B1 (da)
JP (1) JP5762738B2 (da)
KR (1) KR101502518B1 (da)
CN (1) CN101861163B (da)
AR (1) AR060424A1 (da)
AU (1) AU2008238909B2 (da)
BR (1) BRPI0809767B1 (da)
CA (1) CA2683629C (da)
CO (1) CO6260100A2 (da)
DK (1) DK2146742T3 (da)
ES (1) ES2390130T3 (da)
MX (1) MX2009010927A (da)
NZ (1) NZ580533A (da)
RU (1) RU2484134C2 (da)
WO (1) WO2008126039A2 (da)
ZA (1) ZA200907240B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6077735B2 (ja) * 2011-06-08 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
CN105999249A (zh) 2011-10-20 2016-10-12 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
JP6077757B2 (ja) * 2012-04-17 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
JP5921386B2 (ja) * 2012-08-27 2016-05-24 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
CN103146641B (zh) * 2013-02-06 2015-03-25 云南中科灵长类生物医学重点实验室 多能干细胞的传代方法及其用途
CN104990781B (zh) * 2015-06-29 2018-02-16 中国医学科学院皮肤病研究所 黑素细胞免疫组化苏木素—甲苯胺蓝双重复染法
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines
RU2755233C1 (ru) * 2021-01-11 2021-09-14 Сергей Анатольевич Яргунин Способ лечения меланомы кожи IIb-IIc стадий
CN115074328A (zh) * 2022-06-21 2022-09-20 中国人民解放军空军军医大学 一种用于治疗黑素瘤的细胞株及其多效价全细胞疫苗与使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
CA2259140C (en) * 1996-07-10 2008-09-30 Immunex Corporation Method of activating dendritic cells
EP0929318B1 (en) * 1996-08-16 2004-11-24 The Johns Hopkins University School Of Medicine Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DK1224264T3 (da) * 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
WO2001028583A2 (en) * 1999-10-18 2001-04-26 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US20030108527A1 (en) * 1999-12-28 2003-06-12 Tsukasa Seya Maturation-promoting agent for immature dendrtic cells
JP2004512030A (ja) * 2000-09-15 2004-04-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 特異的細胞溶解性ｔ細胞応答を誘導するための組成物および方法
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
EP1390064A4 (en) * 2001-03-09 2006-10-18 Baylor Res Inst METHOD FOR THE TREATMENT OF SACRED ILLNESSES THROUGH EXPOSURE TO BLOOD IMMUNE RESPONSES
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
WO2003057823A2 (en) * 2001-11-07 2003-07-17 Mannkind Corporation Epitope synchronization in antigen presenting cells
RU2348418C2 (ru) * 2002-12-06 2009-03-10 Норсуэст Байотерапьютикс, Инк. Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
RU2262941C2 (ru) 2004-01-05 2005-10-27 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ иммунотерапии злокачественных опухолей головного мозга
US7850962B2 (en) * 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2007536932A (ja) * 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
RU2283129C1 (ru) 2004-12-24 2006-09-10 Сергей Викторович Луценко Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей

Also Published As

Publication number Publication date
AU2008238909A1 (en) 2008-10-23
BRPI0809767B1 (pt) 2022-04-12
CN101861163A (zh) 2010-10-13
CA2683629C (en) 2016-06-21
CO6260100A2 (es) 2011-03-22
CN101861163B (zh) 2013-06-12
MX2009010927A (es) 2010-02-11
ES2390130T3 (es) 2012-11-06
US8501168B2 (en) 2013-08-06
WO2008126039A2 (en) 2008-10-23
EP2146742B1 (en) 2012-07-11
RU2009141593A (ru) 2011-05-20
RU2484134C2 (ru) 2013-06-10
US20100183683A1 (en) 2010-07-22
JP5762738B2 (ja) 2015-08-12
NZ580533A (en) 2012-08-31
AR060424A1 (es) 2008-06-18
JP2010523141A (ja) 2010-07-15
CA2683629A1 (en) 2008-10-23
BRPI0809767A2 (pt) 2014-09-23
EP2146742A2 (en) 2010-01-27
WO2008126039A3 (en) 2008-12-11
KR101502518B1 (ko) 2015-03-13
ZA200907240B (en) 2010-07-28
KR20090129501A (ko) 2009-12-16
AU2008238909B2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
DK2240155T3 (da) Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
DK2331109T3 (da) Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2101819T3 (da) Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK2146742T3 (da) Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK1988090T3 (da) Imidazol-5-carboxylsyrederivater, fremgangsmåder til fremstilling af disse og anvendelse deraf
DK2894165T3 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
DK2120591T3 (da) Ny drikkeyoghurt og fremgangsmåde til fremstilling deraf
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
BRPI0809573A2 (pt) composição, e, método
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK2134663T3 (da) Beskyttelseslag på højtemperaturudholdende chromoxiddannende substrater, og fremgangsmåde til fremstilling deraf